Jutta Steinseifer

2.0k total citations · 1 hit paper
15 papers, 1.5k citations indexed

About

Jutta Steinseifer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jutta Steinseifer has authored 15 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Jutta Steinseifer's work include HER2/EGFR in Cancer Research (8 papers), Advanced Breast Cancer Therapies (8 papers) and Cancer Treatment and Pharmacology (5 papers). Jutta Steinseifer is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Advanced Breast Cancer Therapies (8 papers) and Cancer Treatment and Pharmacology (5 papers). Jutta Steinseifer collaborates with scholars based in Switzerland, United States and Spain. Jutta Steinseifer's co-authors include José Baselga, Semiglazov Vf, Humphrey Gardner, Martine Piccart, Luca Gianni, J. Michael Dixon, Alexey Manikhas, W. Jonat, Richard Greil and Mario Campone and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Jutta Steinseifer

15 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

2009 504 citations José Baselga, Semiglazov Vf et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Jutta Steinseifer

Since Specialization

Citations

This map shows the geographic impact of Jutta Steinseifer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jutta Steinseifer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jutta Steinseifer more than expected).

Fields of papers citing papers by Jutta Steinseifer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jutta Steinseifer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jutta Steinseifer. The network helps show where Jutta Steinseifer may publish in the future.

Co-authorship network of co-authors of Jutta Steinseifer

This figure shows the co-authorship network connecting the top 25 collaborators of Jutta Steinseifer. A scholar is included among the top collaborators of Jutta Steinseifer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jutta Steinseifer. Jutta Steinseifer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Abstract PD13-02: PD13-02 Exploratory gene expression analysis of coopERA Breast Cancer (BC): a study evaluating neoadjuvant giredestrant versus anastrozole alone and in combination with palbociclib in ER-positive, HER2-negative untreated early BC 2023 ·Cancer Research ·Alejandro Chibly, Tharu M. Fernando, Ciara Metcalfe, Marc Hafner, (unknown), Sara A. Hurvitz, Aditya Bardia, Peter A. Fasching, (unknown), Vanesa Quiroga, Jutta Steinseifer, Pablo Ernesto Pérez, Heather M. Moore	2
2	Abstract PD13-06: Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study 2022 ·Cancer Research ·Sara A. Hurvitz, Vanesa Quiroga, Yeon Hee Park, Aditya Bardia, Vanesa López-Valverde, Jutta Steinseifer, Tharu M. Fernando, Gonzalo Spera, (unknown), Peter A. Fasching	6
3	Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study. 2022 ·Journal of Clinical Oncology ·Peter A. Fasching, Aditya Bardia, Vanesa Quiroga, Yeon Hee Park, (unknown), José Luis Alonso-Romero, Alexander Vasilyev, Hryhoriy Adamchuk, (unknown), Denise A. Yardley, Gonzalo Spera, (unknown), (unknown), Tanja Badovinac Črnjević, (unknown), Vanesa López-Valverde, Jutta Steinseifer, Tharu M. Fernando, Heather M. Moore, Sara A. Hurvitz	24
4	LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study 2021 ·Annals of Oncology ·Sara A. Hurvitz, Y.H. Park, Aditya Bardia, Vanesa Quiroga, Vanesa López-Valverde, Jutta Steinseifer, Heather M. Moore, Gonzalo Spera, (unknown), Peter A. Fasching	13
5	Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy 2017 ·Journal of Clinical Oncology ·Dimitrios Zardavas, Thomas Suter, Dirk J. van Veldhuisen, Jutta Steinseifer, Johannes Noé, Sabine Lauer, N. Al-Sakaff, Martine Piccart, Evandro de Azambuja	107
6	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort 2014 ·The Lancet Oncology ·Luca Gianni, W. Eiermann, Semiglazov Vf, Aňa Lluch, Sergei Tjulandin, Milvia Zambetti, Angela Moliterni, Federico Vázquez, M. Byakhov, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Domenico Magazzù, Dominik Heinzmann, Jutta Steinseifer, Pinuccia Valagussa, José Baselga	356
7	Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01) 2014 ·Journal of Clinical Oncology ·Evandro de Azambuja, Marion Procter, Dirk J. van Veldhuisen, Dominique Agbor‐Tarh, Otto Metzger, Jutta Steinseifer, Michael Untch, Ian E. Smith, Luca Gianni, José Baselga, Christian Jackisch, David Cameron, Richard H. Bell, Brian Leyland‐Jones, Mitch Dowsett, Richard D. Gelber, Martine Piccart, Thomas Suter	182
8	Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial. 2013 ·Journal of Clinical Oncology ·Evandro de Azambuja, Marion Procter, (unknown), Dominique Agbor‐Tarh, Otto Metzger, Jutta Steinseifer, Michael Untch, Ian E. Smith, Luca Gianni, José Baselga, Christian Jackisch, David Cameron, Richard H. Bell, Brian Leyland‐Jones, Mitch Dowsett, Richard D. Gelber, Martine Piccart, Thomas Suter	2
9	Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer. 2013 ·Journal of Clinical Oncology ·Luca Gianni, W. Eiermann, Semiglazov Vf, Alexey Manikhas, Aňa Lluch, Sergei Tjulandin, Milvia Zambetti, Federico Vázquez, M. Byakhov, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Domenico Magazzù, Jutta Steinseifer, Pinuccia Valagussa, José Baselga	11
10	Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer 2009 ·Breast Cancer Research and Treatment ·Matthew J. Ellis, Lin Li, Robert J. Crowder, Tao Yu, Jeremy Hoog, Jacqueline Snider, Sherri R. Davies, Katherine DeSchryver, Dean B. Evans, Jutta Steinseifer, Raj Bandaru, Weihua Liu, Humphrey Gardner, Semiglazov Vf, Mark A. Watson, Kelly K. Hunt, John A. Olson, José Baselga	110
11	Phosphatidyl-inositol-3-kinase Alpha catalytic subunit kinase domain mutations impart a favorable prognosis on estrogen receptor positive breast cancer through a mechanism that is independent of responsiveness to endocrine treatment. 2009 ·Cancer Research ·(unknown), Liping Lin, (unknown), Tao Yue, (unknown), Jutta Steinseifer, (unknown), (unknown), Heather Perry Gardner, Semiglazov Vf, José Baselga	1
12	Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer breakdown → 2009 ·Journal of Clinical Oncology ·José Baselga, Semiglazov Vf, Peter van Dam, Alexey Manikhas, Meritxell Bellet, José Mayordomo, Mario Campone, E. Kubista, Richard Greil, Giulia Bianchi, Jutta Steinseifer, (unknown), (unknown), Humphrey Gardner, Penny Phillips, Michael Stumm, Heidi A. Lane, J. Michael Dixon, W. Jonat, Hope S. Rugo	504
13	Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer 2008 ·Journal of Clinical Oncology ·José Baselga, Peter A. van Dam, (unknown), Humphrey Gardner, (unknown), (unknown), Jutta Steinseifer, Patrick Phillips, J. Michael Dixon, H. S. Rugo	14
14	The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics 2007 ·European Journal of Cancer ·Ahmad Awada, Fátima Cardoso, Christel Fontaine, Luc Dirix, Jacques De Grève, Christos Sotiriou, Jutta Steinseifer, Carine Wouters, Chiaki Tanaka, (unknown), (unknown), Martine Piccart	122
15	Internet expert system on breast cancer — Two years experience with a German web site (www.mammakarzinom.de) 1999 ·European Journal of Cancer ·K. Possinger, (unknown), (unknown), M. Kaufmann, Jutta Steinseifer, M. Bamberg, K. Höffken, W. Jonat, R. Kreienberg, Glenn S. Gerhard	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact